Markets:

Overview

News

Currencies

International

Treasuries

(CSE:VIVI)

1.130 -0.110 (-8.87%)

Streaming Delayed Price Updated: 3:59 PM EST, Jan 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about VIVI

TempraMed Receives First Commercial Order from Israel Distributor and Completes Initial Shipment Enabling Entry into National Pharmacy Network

January 06, 2026

Vancouver, British Columbia--(Newsfile Corp. - January 6, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"),...

Via Newsfile

TempraMed Provides Positive Recap on 2025 and Strategic Outlook for 2026

January 02, 2026

Vancouver, British Columbia--(Newsfile Corp. - January 2, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"),...

Via Newsfile

TempraMed Deepens Asian Market Penetration with Expanded Distribution Partnership and Meaningful Commercial Order in South Korea

December 31, 2025

Vancouver, British Columbia--(Newsfile Corp. - December 31, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"),...

Via Newsfile

Topics Intellectual Property

TempraMed Launches New Product, VIVI Cap Smart, Expanding Its Portfolio to Include a Digital Health Offering

December 26, 2025

Highlights: Expands TempraMed's product portfolio and adds a digital component to track and record medication use. First in the world...

Via Newsfile

TempraMed Expands U.S. Manufacturing Capacity with New Production Facility in Florida

December 17, 2025

Highlights: Manufacturing site in Florida expands TempraMed's U.S. production footprintIncreases capacity to meet rising demand from healthcare organizations, pharmacies, payors,...

Via Newsfile

TempraMed Strengthens Global Intellectual Property Position with Grant of South Korean Patent

December 15, 2025

HighlightsNewly granted patent protects TempraMed's VIVI Box™ proprietary, hassle-free thermal-insulation system and smart-monitoring architectureExpands the Company's ability to adapt its...

Via Newsfile

Topics Intellectual Property

TempraMed Appoints Leading Diabetes Researcher Professor Dr. Lutz Heinemann to its Scientific Advisory Board

December 10, 2025

Vancouver, British Columbia--(Newsfile Corp. - December 10, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) ("TempraMed" or the "Company"), a medical...

Via Newsfile

TempraMed Announces Strategic Agreement with Maccabi Healthcare Services, a Leading HMO with over 2.8 Million Patients

December 08, 2025

Vancouver, British Columbia--(Newsfile Corp. - December 8, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) ("TempraMed" or the "Company"), a medical...

Via Newsfile

TempraMed Expands European Footprint with Distribution Partnership in Netherlands, Belgium, and Luxembourg

December 05, 2025

Vancouver, British Columbia--(Newsfile Corp. - December 5, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"),...

Via Newsfile

Topics Economy

TempraMed Signs Exclusive Commercial Distribution Agreement with Leading Distributor to the Turkish Market

December 02, 2025

Dolfin is a well-established, diversified distributor with broad reach across healthcare, hospitals, emergency services, and consumers provides strong potential for...

Via Newsfile

TempraMed Signs Exclusive Distribution Agreement with Leading Consumer Health Distributor in Israel

November 26, 2025

Leading distributor of global companies including GSK/Haleon, Cargill, Reynolds, Paskesz Guri distributes reputable brands including Sensodyne, Aquafresh, Parodontax, Truvia, Diamond...

Via Newsfile

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.